In the BioHarmony Drug Report Database

"Preview" Icon

Revefenacin

Yupelri (revefenacin) is a small molecule pharmaceutical. Revefenacin was first approved as Yupelri on 2018-11-09. It is used to treat chronic obstructive pulmonary disease in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M3, and muscarinic acetylcholine receptor M5. Yupelri’s patents are valid until 2031-08-25 (FDA).

 

Trade Name

 

Yupelri
 

Common Name

 

revefenacin
 

ChEMBL ID

 

CHEMBL3833319
 

Indication

 

chronic obstructive pulmonary disease
 

Drug Class

 

Muscarinic receptor antagonists

Image (chem structure or protein)

Revefenacin structure rendering